Clinical use of SAND battery to evaluate language in patients with Progressive Supranuclear Palsy

Marina Picillo, Sofia Cuoco, Immacolata Carotenuto, Filomena Abate, Roberto Erro, Giampiero Volpe, Maria Teresa Pellecchia, Eleonora Catricalà, Stefano Cappa, Paolo Barone, Marina Picillo, Sofia Cuoco, Immacolata Carotenuto, Filomena Abate, Roberto Erro, Giampiero Volpe, Maria Teresa Pellecchia, Eleonora Catricalà, Stefano Cappa, Paolo Barone

Abstract

Background: Progressive Supranuclear Palsy (PSP) patients present language disturbances in tasks like naming, repetition, reading, word comprehension and semantic association compared to Parkinson's disease (PD) and healthy controls (HC).

Objective: In the present study we sought to validate a Screening for Aphasia in NeuroDegeneration (SAND) battery version specifically tailored on PSP patients and to describe language impairment in relation to PSP disease phenotype and cognitive status.

Methods and results: Fifty-one PSP [23 with Richardson's syndrome (PSP-RS), 10 with predominant parkinsonism (PSP-P) and 18 with the other variant syndromes of PSP (vPSP)], 28 PD and 30 HC were enrolled in the present study. By excluding the tasks with poor acceptability (i.e., writing and picture description tasks) and increasing the items related to the remaining tasks, we showed that the PSP-tailored SAND Global Score is an acceptable, consistent and reliable tool to screen language disturbances in PSP. However, we failed to detect major differences in language involvement according to disease phenotype. Differently, we showed that patients with dementia present worse language performances.

Conclusions: Taking into account specific disease features, the combination of the SAND subscores included in the PSP-tailored SAND better represents language abilities in PSP. Furthermore, we showed that language disturbances feature PSP patients irrespective of disease phenotype, but parallels the deterioration of the global cognitive function.

Conflict of interest statement

PB received consultancies as a member of the advisory board for Zambon, Lundbeck, UCB, Chiesi, Abbvie and Acorda. RE received consultancies from Zambon and honoraria from TEVA. There are no patents, products in development or marketed products associated with this research to declare. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

References

    1. Boxer AL, Yu JT, Golbe LI, Litvan I, Lang AE, Höglinger GU, Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches, Lancet Neurol 2017;16(7):552–563. 10.1016/S1474-4422(17)30157-6
    1. Höglinger GU, Respondek G, Stamelou M, Kurz C, Josephs KA, Lang AE, et al., Movement Disorder Society-endorsed PSP Study Group, Clinical diagnosis of progressive supranuclear palsy: the Movement Disorder Society criteria. Mov Disord 2017;32(6):853–864. 10.1002/mds.26987
    1. Burrell JR, Ballard KJ, Halliday GM, Hodges JR, Aphasia in Progressive Supranuclear Palsy: As Severe as Progressive Non-Fluent Aphasia. Journal of Alzheimer's Disease, 2018;61(2):705–715 10.3233/JAD-170743
    1. Catricalà E, Boschi V, Cuoco S, Galiano F, Picillo M, Gobbi E, et al. The language profile of progressive supranuclear palsy, Cortex 2019;115:294–308. 10.1016/j.cortex.2019.02.013
    1. Battista P, Catricalà E, Piccininni M, Copetti M, Esposito V, Polito C, et al., Screening for Aphasia in NeuroDegeneration for the Diagnosis of Patients with Primary Progressive Aphasia: Clinical Validity and Psychometric Properties. Dementia and Geriatric Cognitive Disorders, 2018;46:243–252. 10.1159/000492632
    1. Catricalà E, Gobbi E, Battista P, Miozzo A, Polito C, Boschi V, et al., SAND: a Screening for Aphasia in NeuroDegeneration. Development and normative data. Neurological Sciences, 2017;38(8):1469–1483. 10.1007/s10072-017-3001-y
    1. Picillo M, Erro R, Cuoco S, Tepedino MF, Manara R, Pellecchia MT, Barone P, MDS PSP Criteria in Real-Life Clinical Setting: Motor and Cognitive Characterization of Subtypes, Mov disord 2017;33(8):1361–1365.
    1. Grimm MJ, Respondek G, Stamelou M, Arzberger T, Ferguson L, et al.; Movement Disorder Society-endorsed PSP Study Group. How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy. Mov Disord Epub 2019. March 18.
    1. Golbe LI, Ohman-Strickland PA, A clinical rating scale for progressive supranuclear palsy. Brain 2007;130:1552–1565. 10.1093/brain/awm032
    1. Santangelo G, Cuoco S, Pellecchia MT, Erro R, Barone P, Picillo M, Comparative cognitive and neuropsychiatric profiles between Parkinson's disease, multiple system atrophy and progressive supranuclear palsy, J Neurol 2018;265(11):2602–2613. 10.1007/s00415-018-9038-x
    1. Kjaergaard M, Arfwedson W, Waterloo K, Jorde R, A study of the psychometric properties of the Beck Depression Inventory-II, the Montgomery and Åsberg Depression Rating Scale, and the Hospital Anxiety and Depression Scale in a sample from a healthy population, Scand J Psychol 2014;55(1):83–89. 10.1111/sjop.12090
    1. Santangelo G, Barone P, Cuoco S, Raimo S, Pezzella D, Picillo M, Vitale C, Apathy in untreated, de novo patients with Parkinson‘s disease: Validation study of apathy evaluation scale, J Neurol 2014;261:2319–2328. 10.1007/s00415-014-7498-1
    1. Picillo M, Cuoco S, Tepedino MF, Cappiello A, Volpe G, Erro R, et al., Motor, cognitive and behavioral differences in MDS PSP phenotypes. Journal of Neurology 2019. April 15 Epub ahead of print
    1. Litvan I, Goldman JG, Tröster AI, Schmand BA, Weintraub D, Petersen RC, et al. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov disord 2012;27(3):349–356. 10.1002/mds.24893
    1. Acquadro C, Joyce CRB, Patrick DL, Ware JE, Wu AW, Scientific Advisory Committee (2004) Linguistic validation manual for patient reported outcomes (PRO) instruments. MAPI Research Institute
    1. Cronbach LJ, Coefficient alpha and the internal structure of tests. Psychometrika 1951;16:297–334.
    1. Scientific Advisory Committee of the Medical Outcomes Trust, Assessing health status and quality-of-life instruments:attributes and review criteria. Qual Life Res 2002;11:193–205.
    1. Nunnally JC, IH Bernstein, Psychometric theory. McGraw-Hill, New York: (1994)
    1. Catricalá E, Della Rosa PA, Ginex V, Mussetti Z Plebani V, Cappa SF. An Italian battery for the assessment of semantic memory disorders. Neurol Sci 2013;34(6):985–993 10.1007/s10072-012-1181-z

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit